– Dr. Jerry Yakatan, Chairman, CEO & Founder of IRISYS, was honored by the city of Jinan in China for his contributions in facilitating international collaboration –
San Diego, December 21, 2018 – Dr. Jerry Yakatan, Chairman, CEO & Founder of IRISYS, was honored by the city of Jinan in China for his contributions in facilitating international collaboration. The city of Jinan developed an Innovation Zone for life science research and tapped Dr. Yakatan’s life-long experience for help. He was honored with a plaque as the International Cooperation Ambassador.
While in China, Dr. Yakatan also attended the 16th Annual Congress of International Drug Discovery Science & Technology (CIDDST) organized by BIT. At this conference, he chaired a session and gave a presentation. In his talk, entitled “Novel Liposomal Drug Delivery Technology,” Dr. Yakatan discussed the advantages and shortcomings of Doxil and Myocet, two liposomal formulations of Doxorubicin, a conventional chemotherapy that exhibits significant off-target toxicity. In his talk, Dr. Yakatan explained that while Doxil has excellent stability in the body, its anti-tumor efficacy is hindered because of its limited release of Doxorubicin. Myocet, on the other hand, releases much more Doxorubicin to the tumor. However, the problem with Myocet is that it leaks significant amounts of Doxorubicin while in the blood stream, which results in undesired off-target effects.
In his presentation, Dr. Yakatan also presented a solution via a Novel pH Targeted Liposomal Drug Delivery System that has been specifically designed to target the extracellular and the intracellular pH differential affecting liposomal drug unloading. The novel pH targeted liposomal drug carrier and its cargo are designed to take advantage of tumor biology and will not just deliver the drug to the tumor site but will make free drug available for the cancer cells, cytoplasm, and nuclei via efficient drug release.
Biotech and pharmaceutical company representatives interested in doing in China or speaking with Dr. Yakatan are welcome to submit the IRISYS contact form.
About IRISYS (irisys.com)
IRISYS was founded in 1996 to provide contract pharmaceutical product development and manufacturing services, specializing in formulation development, cGMP manufacturing of clinical trial materials and commercial pharmaceutical products, and strategic consulting related to the drug development process. IRISYS’ custom approach to drug development is supported by the Company’s scientific and regulatory experience in moving more than 100 drug products from discovery to clinical development and commercialization
Vice President Business Development